Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9277801 | 1.00 | FFAR1 (0.41) | FFAR1GABRA1GABRG2GABRB3GABRB2 | |
| SCHEMBL12013415 | 0.90 | UGT2B17 (0.44) | FFAR1GABRA1GABRG2GABRB3GABRB2 | |
| SCHEMBL9277871 | 0.85 | S1PR1 (0.41) | FFAR1GABRA1GABRG2GABRB3GABRB2 | |
| SCHEMBL1508242 | 0.82 | POLL (0.36) | POLLS1PR1S1PR2S1PR4S1PR3 | |
| SCHEMBL286869 | 0.79 | POLL (0.42) | FFAR1TSHRPTGS1POLLS1PR1 | |
| SCHEMBL21447846 | 0.79 | ACHE (0.44) | FFAR1GABRA1GABRG2GABRB3GABRB2 | |
| SCHEMBL9282154 | 0.77 | POLL (0.40) | FFAR1POLLS1PR1S1PR2S1PR4 | |
| SCHEMBL9282044 | 0.77 | POLL (0.40) | FFAR1POLLS1PR1S1PR2S1PR4 | |
| SCHEMBL9282149 | 0.77 | POLL (0.40) | FFAR1POLLS1PR1S1PR2S1PR4 | |
| SCHEMBL9282760 | 0.77 | POLL (0.40) | FFAR1POLLS1PR1S1PR2S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-8569349-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8338637-B2 | Glaucoma; prostaglandin receptor modulators; cyclopentyl compounds such as 5-{3-[(1S,5S)-5-(3-Chloro-5-hydroxymethyl-phenoxymethyl)-4-oxo-cyclopent-2-enyl]-propyl}-thiophene-2-carboxylic acid | ALLERGAN, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-8252788-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2012-08-28 | — | — | US | disclosed |
| US-8003680-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20110178084-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-7981887-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20110059967-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN INC. (US) | 2011-03-10 | — | — | US | disclosed |
| US-20110059939-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN ,INC (US) | 2011-03-10 | — | — | US | disclosed |
| US-7803797-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-7592366-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2009-09-22 | — | — | US | disclosed |
| US-20080300269-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-7429669-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-20080119538-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080015231-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2008-01-17 | — | — | US | disclosed |
| US-20080015219-A1 | Treating eye diseases including glaucoma or ocular hypertension; selective prostaglandin EP2 agonists; acid-functional aryl substituted cyclopentanone or hydroxycyclopentane compounds | ALLERGAN, INC. | 2008-01-17 | — | — | US | disclosed |
| US-20070293561-A1 | 5-{3-[(1S,5S)-5-(3-Chloro-5-hydroxymethyl-phenoxymethyl)-4-oxo-cyclopent-2-enyl]-propyl}-thiophene-2-carboxylic acid; Treating eye diseases including glaucoma or ocular hypertension; selective prostaglandin EP2 agonists | ALLERGAN, INC. | 2007-12-20 | — | — | US | disclosed |
| US-20070161645-A1 | Thiazole inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161645-A1 | Thiazole inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300269-A1 | THERAPEUTIC COMPOUNDS | THPO, HLA-C, PIGO | FFAR1 3617/4885GABRA1 1150/4885GABRG2 1629/4885 |
| US-20110059939-A1 | THERAPEUTIC COMPOUNDS | CYP11B1, CYP11B2, SLC10A2 | FFAR1 1742/4885GABRA1 1976/4885GABRG2 2898/4885 |
| US-20070293561-A1 | 5-{3-[(1S,5S)-5-(3-Chloro-5-hydroxymethyl-phenoxymethyl)-4-oxo-cyclopent-2-enyl]-propyl}-thiophene-2-carboxylic acid; Treating eye diseases including glaucoma or ocular hypertension; selective prostaglandin EP2 agonists | PTGIR, PTGIS, PTGER2 | FFAR1 232/4885GABRA1 344/4885GABRG2 426/4885 |
| US-20080015219-A1 | Treating eye diseases including glaucoma or ocular hypertension; selective prostaglandin EP2 agonists; acid-functional aryl substituted cyclopentanone or hydroxycyclopentane compounds | PTGER2, PTGER1, PTGS2 | FFAR1 117/4885GABRA1 1330/4885GABRG2 1091/4885 |
| US-20070161645-A1 | Thiazole inhibitors targeting resistant kinase mutations | JAK2, ABL1, FLT3 | FFAR1 3244/4885GABRA1 3182/4885GABRG2 2531/4885 |
| US-20110178084-A1 | THERAPEUTIC COMPOUNDS | DDO, QDPR, SLC10A1 | FFAR1 1792/4885GABRA1 2683/4885GABRG2 3732/4885 |
| US-20110059967-A1 | THERAPEUTIC COMPOUNDS | CYP11B1, CYP11B2, GUCY1B1 | FFAR1 2022/4885GABRA1 2308/4885GABRG2 3086/4885 |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | ABL1, KDR, BCR | FFAR1 2361/4885GABRA1 2637/4885GABRG2 1628/4885 |
| US-20080119538-A1 | THERAPEUTIC COMPOUNDS | GOT2, ANXA5, GOT1 | FFAR1 3833/4885GABRA1 2553/4885GABRG2 2436/4885 |
| US-20080015231-A1 | THERAPEUTIC COMPOUNDS | GOT2, ANXA5, COXFA4L2 | FFAR1 4245/4885GABRA1 3194/4885GABRG2 3075/4885 |
| US-20240025918-A1 | KRAS G12D Inhibitors | KRAS, NRAS, HRAS | FFAR1 3596/4885GABRA1 3975/4885GABRG2 2978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.